REGISTRATION

The 6th ISI is over, but you can still register to get access to the full program and also receive first-hand information about our post-event webinar

Criteria for Registration

Registration for the 6th International Symposium on Immunobiologicals is free of charge and open to both Brazilians and foreigners.
To participate, it is a prerequisite to be a researcher, professional, student or professor in the area of immunobiologicals and related areas, from institutions of production, promotion, technological development of vaccines, biopharmaceuticals or reagents for diagnosis, or from the public health area.

The registration will give the participant access to the virtual platform of the event, with the right to participate in all lectures, visit the exhibition of posters and interact with other participants.

Participation in workshops, mini courses and webinars pre and post event will be made separately, with separate registration forms for each activity, only for participants registered in the 6th ISI.

The organizers may refuse registration to any participant who is not in line with the symposium conduct, or who harms or endangers other participants or the event, at any time, according to their judgment.

6th ISI Schedule

Check the schedule for for the 2022 event

Expand All +
  • May 3rd


  • Sem título

  • Thrombin – Technological development of a national biological sealant
    Fabricio Klerynton Marchini, ICC – Fiocruz / PR*
    Azul

  • Coral da Fiocruz
    – Socorro Gross, PAHO* – Arnaldo Correia de Medeiros, SVS/MoH – Sandra de Castro Barros, SCTIE/MoH – Marco Krieger, Fiocruz* – Mauricio Zuma, Bio-Manguinhos* – Akira Homma, Bio-Manguinhos*

  • VAC-01. Second-generation Vaccines: Adjuvants and Booster Doses
    Gabrielle Gimenes Lima, USP

  • – Ann Ottosen, UNICEF* – Kate O’Brian, WHO* – Andres de Francisco, PAHO* – Akira Homma, Bio-Manguinhos*
    Chair: Mauricio Zuma, Bio-Manguinhos*





  • VAC-03. Recombinant influenza virus encoding a Streptococcus pneumoniae conserved antigen: a bivalent intranasal and intramuscular broad-spectrum vaccine against pneumonia and Flu
    Kimberly Freitas Cardoso, Fiocruz/Instituto René Rachou

  • – South Africa – Caryn Fenner, Afrigen Biologics and Vaccines* – Argentina – German Sanches, Sinergium* – Brazil – Patricia Neves, Bio-Manguinhos*
    Chair: Rami Sharf, PATH*

  • ORT-01. Median Tissue Culture Infectious Dose (TCID50) as a validated tool to measure antiviral activity in functionalized textiles
    Adriana de Souza Azevedo Soares, Bio-Manguinhos

  • – Imelda Jordaan, Afrigen Biologics and Vaccines* – Analía Acebal, Sinergium – Gustavo Mendes, Anvisa
    Chair: Jelena Berglund, PATH

    Azul

  • May 4th


  • Sem título

  • Idea to Injection: Flexible and modular platforms to optimize your manufacturing
    Katarina Stenklo, Cytiva
    Azul

  • – Strategies for collaboration and management of complex projects through the procurement of technology services, Thomas Gerlach, Pannex Therapeutics* – Plant-based production platform as a strategy for acceleration of the development of biologics, Don Stewart, Plantform Canada
    Chair: Hugo Defendi, Bio-Manguinhos*

  • BIO-01. Development and optimization of a protocol for 19BBz CAR-T cells generation
    Leonardo Ribeiro Batista Silva, INCA

  • Talk – innovation hub: Innovative researchers and their innovative startups.
    – Aruã Prudenciatti, CROP – UNESP – Carolina Caliari, In Situ – USP-Ribeirão Preto – Myrian Pruschinski , Skinzymes – USP*
    Chair: Eduardo Emrich, Biominas*
    Azul claro
    Sem título

  • BIO-02. Evaluation of antitumor activity of 5 rna interference in conjunction for the treatment of breast cancer in nude mice
    Ana Beatriz Teixeira Frederico, Bio-Manguinhos


  • – Flexibility and agility in defining and operating a new production site, Eduardo Estrada, Sanofi* – New technologies and strategies in biopharmaceutical manufacturing, Andreas Castan, Cytiva*
    Chair: Luiz Alberto Lima, Bio-Manguinhos*

  • MAN-01. The challenges of VTC-WWTP management in meeting legal requirements in times of COVID-19 pandemic
    Vinícius Mattos de Mello, Bio-Manguinhos

  • – Vaccination of premature babies at CRIE in Brazil – what have we learned? Ana Paula Burian, CRIE / Vitória – ES* – Real-world evidence of hexavalent vaccination introduced in Chile: rational and results, Juan Pablo Torres Torreti, Universidad de Chile*
    Chair: José Cassio de Moraes, Santa Casa de São Paulo*
    Azul

  • May 5th



  • Azul claro
    Sem título

  • The revolutionary potential of mRNA as a platform for biopharma
    Birgit Rogell, Roche CustomBiotech EMEA/LATAM
    Azul

  • – Self-testing experience as a strategy to expand the HIV diagnostic, Mariana Villares, DST-AIDS* – Regulatory framework for new IVD technologies, Marcella Abreu, Anvisa
    Chair: Rosane Cuber, Bio-Manguinhos*




  • IVD-02. New approaches for recombinant protein VP1-2A of HAV production and characterization based on liquid microarray assay: application for developing a point-of care diagnostic test
    Michel Vergne Felix Sucupira, Bio-Manguinhos

  • – The use of large-scale, rapid whole-genome sequencing of SARS-CoV-2 to understand viral transmission and evolution, Lorenzo Subissi, OMS* – Pandemic of SARS- CoV- 2 in Brazil: evolution and emergence of variants of concern, Marilda Siqueira, Fiocruz*
    Chair: Marco Krieger, Fiocruz*

  • IVD-01. Development and Validation of Reverse Transcription Loop- Mediated Isothermal Amplification (RT-LAMP) for Rapid Detection of SARS-CoV-2 in Human Samples
    Bárbara Nazly Rodrigues Santos, Fiocruz

  • – Rebecca Farkas, CEPI* – David Kaslow, PATH* – Peter Dull, B&MGF
    Chair: Sotiris Missailidis, Bio-Manguinhos*


  • – Daniel Pacheco Lacerda, Unisinos* – Maria Cristina de Cunto Brandileone, Adolfo Lutz Institute* – Maria Notomi Sato, USP* – Marco Antonio Stephano, USP* – Paulo Lee Ho, Butantan Institute* – Mauricio Zuma, Bio-Manguinhos*
    Event close-up remarks
    Akira Homma, Bio-Manguinhos











    Cinza escuro

Sponsors

Partners

Realization

This site is registered on wpml.org as a development site.